高齢患者における卵巣がんのスクリーニング (PLCO スクリーニング試験)
前立腺、肺、結腸直腸、および卵巣 (PLCO) がんスクリーニング試験
This clinical trial studies whether screening methods used to diagnose cancer of the prostate, lung, colon, rectum, or ovaries can reduce deaths from these cancers. Screening tests may help doctors find cancer cells early and plan better treatment for ovarian cancer. The ovarian cancer screening tests are part of a trial that addresses the screening of four cancer sites, each with their own results record: prostate (NCT00002540), lung (NCT01696968), colorectal (NCT01696981), and ovarian (NCT01696994).
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
PRIMARY OBJECTIVES:
I. To determine whether screening with CA125 and transvaginal ultrasound (TVU) can reduce mortality from ovarian cancer in women aged 55-74 at entry.
SECONDARY OBJECTIVES:
I. To assess screening variables, other than mortality, for each of the interventions including sensitivity, specificity, and positive predictive value.
II. To assess the incidence, stage, and survival of cancer cases. III. To investigate the mortality predictive value of biologic and/or prognostic characterizations of tumor tissue as intermediate endpoints.
IV. To conduct biomolecular and genetic research into factors associated with cancer carcinogenesis and promotion, as well as the early detection of these factors.
OUTLINE: Participants in the overall PLCO study are stratified by screening center, gender, and age (55-59 vs 60-64 vs 65-69 vs 70-74). Participants are randomized to 1 of 2 arms (control vs screening).
ARM I (Control): Participants receive standard medical care. Participants complete a Diet History Questionnaire (DHQ) at baseline.
ARM II (Ovarian Screening): Participants undergo blood sample collection for CA125 analysis at baseline annually for 5 years. Serum that is not used in the study will be stored in an NCI biorepository. Participants also undergo an ovarian palpation exam (OVR, discontinued in December 1998) and TVU at baseline and annually for 3 years. A scheduling and tracking procedure is implemented to ensure regular attendance at repeat screens for participants screened negative or for those who are designated suspicious or positive at screening but for whom subsequent diagnostic procedures do not reveal ovarian cancer (follow-up diagnostic procedures are through their own medical care environment). Participants diagnosed with ovarian cancer via a screening test are referred for treatment in accordance with current accepted practice for appropriate stage of disease, patient age, and medical condition; a procedure is provided for contact with qualified medical personnel to insure appropriate therapy.
Participants complete a Dietary Questionnaire (DQX) at baseline and DHQ at year 3. An Annual Study Update (ADU) (previously referred to as the Periodic Survey of Health [PSH] questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident cancers of the ovaries as all deaths that occur among both screened and control subjects during the trial.
After completion of screening, participants are followed up for at least 13 years.
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- 適用できない
連絡先と場所
研究場所
-
-
Maryland
-
Bethesda、Maryland、アメリカ、20892
- National Institutes of Health Clinical Center
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Exclusion Criteria:
-
Women who at the time of randomization are less than 55 or greater than or equal to 75 years of age
-
Individuals undergoing treatment for cancer at this time, excluding basal-cell and squamous-cell skin cancer
-
Individuals with known prior cancer of the colon, rectum, lung, or ovary
- This includes primary or metastatic PLCO cancers
-
Individuals with previous surgical removal of the entire colon or one lung
- Until October 1996, women with previous surgical removal of both ovaries were excluded from the trial. In order to increase the enrollment of women into the trial, beginning in October 1996, these women were no longer excluded for this reason.
-
Individuals who are participating in another cancer screening or cancer primary prevention trial
-
Prior to April 1, 1999 women were excluded from the trial if they were currently taking or had taken Tamoxifen or Evista\Raloxifene in the past 6 months. As of April 1999 based on a decision from the PLCO Ovary Subcommittee, women who have or are currently taking Tamoxifen or Evista\Raloxifene are not excluded from participation.
-
Individuals who are unwilling or unable to sign the informed consent form
-
Individuals who have had a colonoscopy, sigmoidoscopy, or barium enema in the past three years
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:ふるい分け
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
介入なし:Control
Participants receive standard medical care. Participants complete a DHQ at baseline. |
|
|
アクティブコンパレータ:Ovarian Screening
Participants undergo blood sample collection for CA125 analysis at baseline annually for 5 years. Serum that is not used in the study will be stored in an NCI biorepository. Participants also undergo an OVR (discontinued in December 1998) and TVU at baseline and annually for 3 years. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident cancers of the ovaries as all deaths that occur among both screened and control subjects during the trial. |
Correlative studies Undergo questionnaire assessments Undergo TVU
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Ovarian Cancer Deaths (Including Primary Peritoneal and Fallopian Tube Cancers)
時間枠:Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
Ovarian cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate. |
Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
|
Ovarian Cancer Death Rates (Including Primary Peritoneal and Fallopian Tube Cancers)
時間枠:Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
Ovarian cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate. Rate is the number of deaths divided by person years of follow-up in the study. |
Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Deaths From All Causes
時間枠:Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
Deaths from all causes were compared between the ovarian cancer screening arm and the usual care arm. |
Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
|
Death Rates From All Causes
時間枠:Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
Deaths from all causes were compared between the ovarian cancer screening arm and the usual care arm. Rate is the number of deaths divided by person years of follow-up in the study. |
Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
|
Ovarian Cancer Incidence (Including Primary Peritoneal and Fallopian Tube Cancers)
時間枠:Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
Ovarian cancer diagnoses confirmed by medical record abstraction. |
Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
|
Ovarian Cancer Incidence Rates (Including Primary Peritoneal and Fallopian Tube Cancers).
時間枠:Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
Ovarian cancer diagnoses confirmed by medical record abstraction. Incidence rate (cumulative) defined as ovarian cancer diagnoses divided by person years at risk for ovarian cancer. |
Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
|
Complications of Diagnostic Evaluation (DE) Following a Positive Screening Test
時間枠:One year from screening examination
|
Number of positive screens with complications |
One year from screening examination
|
|
T0 (Baseline) CA-125 Screening Results
時間枠:T0 (at study entry)
|
Cancer Antigen 125 (CA-125) result. |
T0 (at study entry)
|
|
T0 (Baseline) TVU Screening Results
時間枠:T0 (at study entry)
|
Transvaginal Ultrasound (TVU) result. |
T0 (at study entry)
|
|
T1 CA-125 Screening Results
時間枠:T1 (one year after entry)
|
Cancer Antigen 125 (CA-125) result. |
T1 (one year after entry)
|
|
T1 TVU Screening Results
時間枠:T1 (one year after entry)
|
Transvaginal Ultrasound (TVU) result. |
T1 (one year after entry)
|
|
T2 CA-125 Screening Results
時間枠:T2 (two years after entry)
|
Cancer Antigen 125 (CA-125) result. |
T2 (two years after entry)
|
|
T2 TVU Screening Results
時間枠:T2 (one year after entry)
|
Transvaginal Ultrasound (TVU) result. |
T2 (one year after entry)
|
|
T3 CA-125 Screening Results
時間枠:T3 (three years after entry)
|
Cancer Antigen 125 (CA-125) result. |
T3 (three years after entry)
|
|
T3 TVU Screening Results
時間枠:T3 (three years after entry)
|
Transvaginal Ultrasound (TVU) result. |
T3 (three years after entry)
|
|
T4 CA-125 Screening Results
時間枠:T4 (four years after entry)
|
Cancer Antigen 125 (CA-125) result. |
T4 (four years after entry)
|
|
T5 CA-125 Screening Results
時間枠:T5 (five years after entry)
|
Cancer Antigen 125 (CA-125) result. |
T5 (five years after entry)
|
協力者と研究者
捜査官
捜査官
- 主任研究者:Christine D Berg、National Cancer Institute (NCI)
出版物と役立つリンク
一般刊行物
- Jiang Y, Xie Q, Chen R. Breast Cancer Incidence and Mortality in Relation to Hormone Replacement Therapy Use Among Postmenopausal Women: Results From a Prospective Cohort Study. Clin Breast Cancer. 2022 Feb;22(2):e206-e213. doi: 10.1016/j.clbc.2021.06.010. Epub 2021 Jun 26.
- Wang K, Wu Q, Li Z, Reger MK, Xiong Y, Zhong G, Li Q, Zhang X, Li H, Foukakis T, Xiang T, Zhang J, Ren G. Vitamin K intake and breast cancer incidence and death: results from a prospective cohort study. Clin Nutr. 2021 May;40(5):3370-3378. doi: 10.1016/j.clnu.2020.11.009. Epub 2020 Nov 16.
- Malcomson FC, Shams-White MM, Reedy J, Huang WY, Moore SC, Loftfield E. Adherence to the 2018 World Cancer Research Fund/American Institute for Cancer Research Cancer Prevention Recommendations and risk of lifestyle-related cancers in the prostate, lung, colorectal, and ovarian cancer screening trial. BJC Rep. 2025 Nov 19;3(1):81. doi: 10.1038/s44276-025-00195-6.
- Fan Z, Zhang Y, Yao Q, Liu X, Duan H, Liu Y, Sheng C, Lyu Z, Yang L, Song F, Huang Y, Song F. Effects of joint screening for prostate, lung, colorectal, and ovarian cancer - results from a controlled trial. Front Oncol. 2024 Apr 29;14:1322044. doi: 10.3389/fonc.2024.1322044. eCollection 2024.
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (推定)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- NCI-2012-01758
- CDR0000078532
- NCI-P93-0050
- PLCO-1
- NCI-2012-01758 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
- PLCO-Ovarian (その他の識別子:National Cancer Institute)
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。